## Five-year risk of incident pancreatic cancer in patients with type 2 diabetes (comparison between propensity-score matched groups: GLP-1RAs vs other anti-diabetes medications)

Size/group	Exposure group	Comparison group	# of cases (overall risk) (Exposure group)	# of cases (overall risk) (Comparison group)		HR (95% CI)
51,857	GLP-1RA(+)Insulin(-)	Insulin(+)GLP-1RA(-)	100 (0.19%)	213 (0.41%)	<b>├──</b>	0.42 (0.33–0.53)
34,197	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	111 (0.33%)	142 (0.42%)	<b>├──</b>	0.74 (0.58–0.95)
93,237	GLP-1RA(+)DDP-4i(-)	DPP-4i(+)GLP-1RA(-)	305 (0.33%)	361 (0.39%)	<b>├-</b>	0.77 (0.66–0.90)
51,028	GLP-1RA(+)SGLTi2(-)	SGLT2i(+)GLP-1RA(-)	199 (0.39%)	258 (0.51%)	<del>  ■  </del>	0.71 (0.59–0.85)
81,514	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	243 (0.30%)	302 (0.37%)	<b>├</b> - <b>■</b>	0.74 (0.63–0.88)
53,906	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	215 (0.40%)	244 (0.45%)	<b>├</b> - <b>■</b>	0.82 (0.69–0.99)
				(	0.30 0.40 0.50 0.70 0.90 Hazard Ra	3.00